282
Views
18
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia

, , , , , , , , , , & show all
Pages 275-278 | Received 22 Sep 2009, Accepted 21 Nov 2009, Published online: 28 Dec 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lingyun Geng & Xin Wang. (2015) New insight into hedgehog signaling in hematological malignancies. Leukemia & Lymphoma 56:4, pages 858-865.
Read now

Articles from other publishers (17)

Nicholas J. Short, Jayastu Senapati & Elias Jabbour. (2023) An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 18:6, pages 234-242.
Crossref
Stephen E. Langabeer, Stuart Macleod, Úna Bhreathnach & Kamal Fadalla. (2023) Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation. Case Reports in Hematology 2023, pages 1-2.
Crossref
Jayastu Senapati, Elias Jabbour, Hagop Kantarjian & Nicholas J. Short. (2022) Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37:1, pages 5-17.
Crossref
Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak & Katerina Machova Polakova. (2021) Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining. Frontiers in Oncology 11.
Crossref
Federico Lussana, Tamara Intermesoli, Paola Stefanoni & Alessandro Rambaldi. 2018. Mechanisms of Drug Resistance in Cancer Therapy. Mechanisms of Drug Resistance in Cancer Therapy 231 250 .
TaeHyung Kim, Marc S. TyndelHyeoung Joon Kim, Jae-Sook Ahn, Seung Hyun ChoiHee Jeong ParkYeo-kyeoung KimSoo Young KimJeffrey H. Lipton, Zhaolei Zhang & Dennis (Dong Hwan) Kim. (2017) Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 129:1, pages 38-47.
Crossref
D W Woessner, A M Eiring, B J Bruno, M S Zabriskie, K R Reynolds, G D Miller, T O'Hare, M W Deininger & C S Lim. (2015) A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia 29:8, pages 1668-1675.
Crossref
Naval Daver, Jorge Cortes, Farhad Ravandi, Keyur P. Patel, Jan A. Burger, Marina Konopleva & Hagop Kantarjian. (2015) Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125:21, pages 3236-3245.
Crossref
Federica Lovisa, Giorgio Cozza, Andrea Cristiani, Alberto Cuzzolin, Alessandro Albiero, Lara Mussolin, Marta Pillon, Stefano Moro, Giuseppe Basso, Angelo Rosolen & Paolo Bonvini. (2015) ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. PLOS ONE 10:4, pages e0121378.
Crossref
Dong-Sheng Lian & Shu-Jin Zhao. (2014) Capillary electrophoresis based on the nucleic acid detection in the application of cancer diagnosis and therapy. The Analyst 139:14, pages 3492-3506.
Crossref
Zafar Iqbal, Aamer Aleem, Mudassar Iqbal, Mubashar Iqbal Naqvi, Ammara Gill, Abid Sohail Taj, Abdul Qayyum, Najeeb ur-Rehman, Ahmad Mukhtar Khalid, Ijaz Hussain Shah, Muhammad Khalid, Riazul Haq, Mahwish Khan, Shahid Mahmood Baig, Abid Jamil, Muhammad Naeem Abbas, Muhammad Absar, Amer Mahmood, Mahmood Rasool & Tanveer Akhtar. (2013) Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era. PLoS ONE 8:2, pages e55717.
Crossref
Eran Eyal, Tali Tohami, Amnon Amir, Karen Cesarkas, Jasmine Jacob‐Hirsch, Yuliya Volchek, Arnon Nagler, Gideon Rechavi & Ninette Amariglio. (2012) Detection of BCR ‐ ABL 1 mutations in chronic myeloid leukaemia by massive parallel sequencing . British Journal of Haematology 160:4, pages 477-486.
Crossref
Stefania Aliano, Gabriella Cirmena, Giuseppina Fugazza, Roberto Bruzzone, Claudia Palermo & Mario Sessarego. (2013) Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy. Leukemia Research Reports 2:2, pages 75-78.
Crossref
Wanwisa Wongboonma, Wanna Thongnoppakhun & Chirayu U. Auewarakul. (2012) BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Experimental and Molecular Pathology 92:2, pages 259-265.
Crossref
Marie P. ShiehMasato MitsuhashiMichael Lilly. (2011) Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clinical Medicine Insights: Oncology 5, pages CMO.S6416.
Crossref
Paula Kinsella, Martin Clynes & Verena Amberger-Murphy. (2010) Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. Journal of Neuro-Oncology 101:2, pages 189-198.
Crossref
A. M. Carella. (2010) Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?. Annals of Hematology 89:6, pages 531-533.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.